Optimization of initial tacrolimus dose using pharmacogenetic testing

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 721-726

  Thervet, E ^a,b   Loriot, M A ^c   Barbier, S ^d   Buchler, M ^e   Ficheux, M ^f   Choukroun, G ^g   Toupance, O ^h   Touchard, G ⁱ   Alberti, C ^j   Le Pogamp, P ^k   Moulin, B ^l   Le Meur, Y ^m   Heng, A E ⁿ   Subra, J F ^o   Beaune, P ^c   Legendre, C ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j HÔPITAL ROBERT DEBRÉ   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^m BREST UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^o ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYTOCHROME P450 3A5; FLUCONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL TOXICITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; INFECTION; INFESTATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NUTRITIONAL DEFICIENCY; NUTRITIONAL DISORDER; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHARMACOGENETICS; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 77952585319     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.17     Document Type: Article

References (21)

1. Margreiter, R. Efcacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359, 741-746 (2002). (Pubitemid 34215073)
2. Wallemacq, P. et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 31, 139-152 (2009).
3. Lee, S.j. et al. Genetic fndings and functional studies of human CYP3A5 single nucleotide polymorphisms in diferent ethnic groups. Pharmacogenetics 13, 461-472 (2003).
4. Goto, M. et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14, 471-478 (2004).
5. Haufroid, V. et al. The efect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004).
6. Thervet, E. et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76, 1233-1235 (2003).
7. Zheng, H. et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3, 477-483 (2003).
8. Zheng, H. et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 44, 135-140 (2004).
9. MacPhee, I.A. et al. The infuence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4, 914-919 (2004).
10. Haufroid, V. et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant. 6, 2706-2713 (2006).
11. Uesugi, M., Masuda, S., Katsura, T., Oike, F., Takada, Y. & Inui, K. Efect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics 16, 119-127 (2006).
12. Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562-2575 (2007).
13. Xie, H.G., Wood, A.j., Kim, R.B., Stein, C.M. & Wilkinson, G.R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5, 243-272 (2004).
14. Mancinelli, L.M. et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69, 24-31 (2001).
15. Undre, N.A. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol. Dial. Transplant. 18(suppl. 1), i12-i15 (2003).
16. Undre, N.A. et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant. Proc. 31, 296-298 (1999).
17. Christians, U., jacobsen, W., Benet, L.Z. & Lampen, A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 41, 813-851 (2002).
18. Mignat, C. Clinically signifcant drug interactions with new immunosuppressive agents. Drug Saf. 16, 267-278 (1997).
19. Anglicheau, D. et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14, 1889-1896 (2003).
20. Hashida, T., Masuda, S., Uemoto, S., Saito, H., Tanaka, K. & Inui, K. Pharmacokinetic and prognostic signifcance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin. Pharmacol. Ther. 69, 308-316 (2001).
21. Macphee, I.A. et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74, 1486-1489 (2002).